Compare Stocks: TELO, CLLS, FATE, and RNAC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$3.40 -2.0%	$2.95	$2.35 ▼ $5.48	$341.65M	2.91	18,392 shs	26,655 shs
FATE Fate Therapeutics	$2.33 -4.9%	$2.56	$0.93 ▼ $3.23	$279.18M	2.52	2.04 million shs	1.68 million shs
RNAC Cartesian Therapeutics	$10.04 -1.9%	$9.04	$5.60 ▼ $11.80	$303.76M	0.63	133,122 shs	163,904 shs
TELO Telomir Pharmaceuticals	$1.13	$1.20	$0.89 ▼ $2.09	$77.72M	-0.24	59,973 shs	43,317 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	0.00%	+11.48%	+22.74%	-2.86%	+20.57%
FATE Fate Therapeutics	0.00%	-9.34%	-7.54%	+3.56%	+106.19%
RNAC Cartesian Therapeutics	0.00%	+13.57%	+26.77%	+48.74%	-9.30%
TELO Telomir Pharmaceuticals	0.00%	+3.67%	-2.59%	-12.40%	-22.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$3.40 -2.0%	$2.95	$2.35 ▼ $5.48	$341.65M	2.91	18,392 shs	26,655 shs
FATE Fate Therapeutics	$2.33 -4.9%	$2.56	$0.93 ▼ $3.23	$279.18M	2.52	2.04 million shs	1.68 million shs
RNAC Cartesian Therapeutics	$10.04 -1.9%	$9.04	$5.60 ▼ $11.80	$303.76M	0.63	133,122 shs	163,904 shs
TELO Telomir Pharmaceuticals	$1.13	$1.20	$0.89 ▼ $2.09	$77.72M	-0.24	59,973 shs	43,317 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	0.00%	+11.48%	+22.74%	-2.86%	+20.57%
FATE Fate Therapeutics	0.00%	-9.34%	-7.54%	+3.56%	+106.19%
RNAC Cartesian Therapeutics	0.00%	+13.57%	+26.77%	+48.74%	-9.30%
TELO Telomir Pharmaceuticals	0.00%	+3.67%	-2.59%	-12.40%	-22.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	2.83	Moderate Buy	$7.00	105.88% Upside
FATE Fate Therapeutics	2.38	Hold	$5.90	153.22% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	224.70% Upside
TELO Telomir Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest TELO, CLLS, FATE, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/7/2026	FATE Fate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	CLLS Cellectis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TELO Telomir Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/30/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/12/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/10/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$79.59M	4.29	N/A	N/A	$0.41 per share	8.29
FATE Fate Therapeutics	$6.49M	43.01	N/A	N/A	$1.28 per share	1.82
RNAC Cartesian Therapeutics	$2.80M	108.47	N/A	N/A	($4.14) per share	-2.43
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$67.59M	-$0.65	N/A	N/A	N/A	-102.34%	-94.19%	-21.34%	11/9/2026 (Estimated)
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	11/5/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	9/2/2026 (Estimated)

Latest TELO, CLLS, FATE, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	N/A	TELO Telomir Pharmaceuticals	-$0.07	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A
8/6/2026	H1 2026	CLLS Cellectis	-$0.2630	-$0.22	+$0.0430	-$0.22	$11.05 million	$6.90 million
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	1.61	1.37	1.37
FATE Fate Therapeutics	N/A	4.85	4.85
RNAC Cartesian Therapeutics	N/A	7.48	7.48
TELO Telomir Pharmaceuticals	N/A	16.16	16.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
FATE Fate Therapeutics	97.54%
RNAC Cartesian Therapeutics	86.95%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
FATE Fate Therapeutics	4.74%
RNAC Cartesian Therapeutics	37.20%
TELO Telomir Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	100.34 million	83.87 million	Optionable
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable
RNAC Cartesian Therapeutics	64	30.25 million	19.00 million	Optionable
TELO Telomir Pharmaceuticals	1	68.78 million	57.52 million	N/A

TELO, CLLS, FATE, and RNAC Headlines

Recent News About These Companies

Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results

August 13, 2026 | marketbeat.com

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?

August 12, 2026 | defenseworld.netD

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% - Should You Sell?

August 12, 2026 | marketbeat.com

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

August 10, 2026 | markets.businessinsider.com

Telomir-Zn Preclinical Data Support Advancement in TNBC

August 10, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models

August 10, 2026 | quiverquant.comQ

TELO Telomir Pharmaceuticals, Inc.

July 8, 2026 | seekingalpha.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...

June 15, 2026 | usatoday.com

Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data

June 15, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

June 15, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change

June 8, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral$

Telomir Pharmaceuticals Inc TELO

May 26, 2026 | morningstar.comM

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease

May 20, 2026 | usatoday.com

Telomir-Zn Preclinical Data Published in Wilson’s Disease

May 20, 2026 | tipranks.com

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

May 20, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn

April 30, 2026 | tipranks.com

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

April 30, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

April 24, 2026 | usatoday.com

Telomir Pharmaceuticals Inc.

April 2, 2026 | barrons.com

Telomir seeks FDA approval for Telomir-1 to treat breast cancer

April 2, 2026 | msn.com

Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance

March 31, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, CLLS, FATE, and RNAC Company Descriptions

Cellectis NASDAQ:CLLS

$3.40 -0.07 (-2.02%)

As of 08/21/2026 03:59 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Fate Therapeutics NASDAQ:FATE

$2.33 -0.12 (-4.90%)

As of 08/21/2026 04:00 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Cartesian Therapeutics NASDAQ:RNAC

$10.04 -0.19 (-1.86%)

As of 08/21/2026 04:00 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Telomir Pharmaceuticals NASDAQ:TELO

$1.13 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, CLLS, FATE, and RNAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, CLLS, FATE, and RNAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, CLLS, FATE, and RNAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, CLLS, FATE, and RNAC Company Descriptions

Cellectis NASDAQ:CLLS

Fate Therapeutics NASDAQ:FATE

Cartesian Therapeutics NASDAQ:RNAC

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, CLLS, FATE, and RNAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, CLLS, FATE, and RNAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, CLLS, FATE, and RNAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, CLLS, FATE, and RNAC Company Descriptions

Cellectis NASDAQ:CLLS

Fate Therapeutics NASDAQ:FATE

Cartesian Therapeutics NASDAQ:RNAC

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools